MX2017002986A - Compuestos de piperidina sustituidos. - Google Patents
Compuestos de piperidina sustituidos.Info
- Publication number
- MX2017002986A MX2017002986A MX2017002986A MX2017002986A MX2017002986A MX 2017002986 A MX2017002986 A MX 2017002986A MX 2017002986 A MX2017002986 A MX 2017002986A MX 2017002986 A MX2017002986 A MX 2017002986A MX 2017002986 A MX2017002986 A MX 2017002986A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- substituted piperidine
- present disclosure
- piperidine compounds
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente descripción proporciona compuestos de piperidina sustituidos que tienen la Formula I: (ver formula I) y las sales y solvatos farmacéuticamente aceptables de los mismos, en donde R1, B, X y Z se definen como se recoge en la memoria descriptiva. La presente descripción también se dirige al use de compuestos de Formula I para tratar un trastorno que responde al bloqueo de proteínas SMYD tales como SMYD3 o SMYD2. Compuestos de la presente descripción son especialmente Útiles para tratar el cáncer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462048771P | 2014-09-10 | 2014-09-10 | |
US201462078845P | 2014-11-12 | 2014-11-12 | |
US201562146790P | 2015-04-13 | 2015-04-13 | |
PCT/US2015/049235 WO2016040515A1 (en) | 2014-09-10 | 2015-09-09 | Substituted piperidine compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017002986A true MX2017002986A (es) | 2017-10-24 |
Family
ID=55459535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017002986A MX2017002986A (es) | 2014-09-10 | 2015-09-09 | Compuestos de piperidina sustituidos. |
Country Status (13)
Country | Link |
---|---|
US (1) | US10577363B2 (es) |
EP (1) | EP3193605A4 (es) |
JP (1) | JP2017528464A (es) |
KR (1) | KR20170047397A (es) |
CN (1) | CN107072207A (es) |
AU (1) | AU2015315182A1 (es) |
BR (1) | BR112017004589A2 (es) |
CA (1) | CA2960280A1 (es) |
EA (1) | EA201790327A1 (es) |
IL (1) | IL250888A0 (es) |
MX (1) | MX2017002986A (es) |
SG (2) | SG10201901189SA (es) |
WO (1) | WO2016040515A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10179773B2 (en) | 2014-09-10 | 2019-01-15 | Epizyme, Inc. | Isoxazole carboxamides as irreversible SMYD inhibitors |
US10106510B2 (en) | 2014-09-10 | 2018-10-23 | Epizyme, Inc. | Substituted isoxazoles for treating cancer |
JP2017538659A (ja) | 2014-09-10 | 2017-12-28 | エピザイム インコーポレイテッド | Smyd阻害剤 |
WO2016040498A1 (en) | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Isoxazole carboxamide compounds |
EP3263572B1 (en) * | 2015-02-27 | 2021-12-15 | Seed Research Institute Co., Ltd. | Method for producing kakeromycin and derivatives thereof |
MX2019001042A (es) * | 2016-07-28 | 2019-06-10 | Idorsia Pharmaceuticals Ltd | Derivados de piperidina. |
WO2018151678A1 (en) * | 2017-02-15 | 2018-08-23 | Agency For Science, Technology And Research | Compounds for treatment of cancer and epigenetics |
CA3088478A1 (en) * | 2018-01-26 | 2019-08-01 | Idorsia Pharmaceuticals Ltd | Crystalline forms of the cxcr7 receptor antagonist (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide |
WO2021065898A1 (ja) | 2019-09-30 | 2021-04-08 | 日本ケミファ株式会社 | アゼパン誘導体 |
CN114702552B (zh) * | 2022-03-11 | 2024-05-31 | 苏州思萃免疫技术研究所有限公司 | mTORC2抑制剂 |
WO2024067708A1 (zh) * | 2022-09-30 | 2024-04-04 | 苏州阿尔脉生物科技有限公司 | 草酸胺类衍生物、包含其的药物组合物及其医药用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1228288B (it) * | 1989-01-09 | 1991-06-07 | Zambon Spa | Composti ad attivita' antiserotoninica |
SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
SE0403106D0 (sv) | 2004-12-20 | 2004-12-20 | Astrazeneca Ab | Chemical compounds |
US20090062286A1 (en) | 2007-05-04 | 2009-03-05 | Kenneth William Foreman | Crystal Structure of SMYD3 Protein |
WO2009072643A1 (en) * | 2007-12-03 | 2009-06-11 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound and use thereof |
TWI535712B (zh) * | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
US9045485B2 (en) * | 2010-12-16 | 2015-06-02 | Convergence Pharmaceuticals Limited | ASK 1 inhibiting pyrrolopyrimidine derivatives |
EP3193604B1 (en) | 2014-09-10 | 2021-06-16 | Epizyme, Inc. | Substituted n-(pyrrolidin-3-yl)isoxazole-3-carboxamide compounds |
JP2017538659A (ja) | 2014-09-10 | 2017-12-28 | エピザイム インコーポレイテッド | Smyd阻害剤 |
US10106510B2 (en) | 2014-09-10 | 2018-10-23 | Epizyme, Inc. | Substituted isoxazoles for treating cancer |
US10179773B2 (en) | 2014-09-10 | 2019-01-15 | Epizyme, Inc. | Isoxazole carboxamides as irreversible SMYD inhibitors |
AU2015315177A1 (en) | 2014-09-10 | 2017-03-16 | Epizyme, Inc. | Substituted pyrrolidine carboxamide compounds |
WO2016040498A1 (en) | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Isoxazole carboxamide compounds |
-
2015
- 2015-09-09 SG SG10201901189SA patent/SG10201901189SA/en unknown
- 2015-09-09 EA EA201790327A patent/EA201790327A1/ru unknown
- 2015-09-09 CA CA2960280A patent/CA2960280A1/en not_active Abandoned
- 2015-09-09 AU AU2015315182A patent/AU2015315182A1/en not_active Abandoned
- 2015-09-09 WO PCT/US2015/049235 patent/WO2016040515A1/en active Application Filing
- 2015-09-09 MX MX2017002986A patent/MX2017002986A/es unknown
- 2015-09-09 KR KR1020177009316A patent/KR20170047397A/ko unknown
- 2015-09-09 JP JP2017513207A patent/JP2017528464A/ja active Pending
- 2015-09-09 BR BR112017004589A patent/BR112017004589A2/pt not_active Application Discontinuation
- 2015-09-09 EP EP15840497.0A patent/EP3193605A4/en not_active Withdrawn
- 2015-09-09 CN CN201580060918.8A patent/CN107072207A/zh active Pending
- 2015-09-09 SG SG11201701597RA patent/SG11201701597RA/en unknown
- 2015-09-09 US US15/510,588 patent/US10577363B2/en active Active
-
2017
- 2017-03-02 IL IL250888A patent/IL250888A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN107072207A (zh) | 2017-08-18 |
AU2015315182A1 (en) | 2017-03-16 |
KR20170047397A (ko) | 2017-05-04 |
US10577363B2 (en) | 2020-03-03 |
IL250888A0 (en) | 2017-04-30 |
SG11201701597RA (en) | 2017-03-30 |
SG10201901189SA (en) | 2019-03-28 |
BR112017004589A2 (pt) | 2018-01-23 |
JP2017528464A (ja) | 2017-09-28 |
US20170362217A1 (en) | 2017-12-21 |
EP3193605A4 (en) | 2018-04-18 |
WO2016040515A1 (en) | 2016-03-17 |
EA201790327A1 (ru) | 2017-10-31 |
EP3193605A1 (en) | 2017-07-26 |
CA2960280A1 (en) | 2016-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023006257A (es) | Inhibidores de smyd. | |
MX2017002986A (es) | Compuestos de piperidina sustituidos. | |
PH12019501321B1 (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders | |
MX2018012379A (es) | Degradadores de proteinas de bromodominio y dominioextraterminal (bet). | |
PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
MX2018013433A (es) | Piperidinas como inhibidores de menina. | |
MX2020012165A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer. | |
MD20160106A2 (ro) | Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4 | |
MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
MX2015013481A (es) | Compuestos heterociclicos fusionados como inhibidores de proteina quinasa. | |
NZ727185A (en) | Phosphatidylinositol 3-kinase inhibitors | |
MA40170A (fr) | Dérivés hétérocycliques de morphinan et leur utilisation | |
PH12015502611A1 (en) | Heterocyclic compounds as hedgehog signaling pathway inhibitors | |
MX2018004664A (es) | Antagonistas de ep4. | |
PH12016502394A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
PH12014501712B1 (en) | Novel morpholinyl derivatives useful as mogat-2-inhibitors | |
IN2013MU03862A (es) | ||
PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
PH12017501214A1 (en) | Cgrp antagonist peptides | |
TN2014000307A1 (en) | Novel morpholinyl derivatives useful as mogat-2 inhibitors |